FDA written feedback supports:- a single-arm, open-label registrational trial in 2nd-line refractory high-grade NMIBC with CIS- a randomized vs ...
The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive ...
Shattuck Labs (STTK) pivots from oncology to focus on SL-325 for inflammatory bowel disorders, following underwhelming ...
Larian Studios head of design Nick Pechenin stepped in to answer a question about Divinity's loot system, explaining that the ...
Data suggest that when pharmacological Zn levels used, average daily gain and average daily feed intake can be improved with ...
Although a 2024 collab produced one of the best LEGO sets in recent memory, even the most hardcore fans may never complete ...
The NEO-CYT study, sponsored by Fondazione Melanoma Onlus, will be evaluating MDNA11 in front-line therapy for resectable ...
Laura holds a Master's in Experimental Neuroscience and a Bachelor's in Biology from Imperial College London. Her areas of ...
Survive in the ancient clockwork world of Elysium in this airship survival RPG set in the heavens of mythical ancient Greece.
Revolution Medicines surged on AbbVie buyout rumors but pulled back after denial. Learn what's next for RVMD stock and why it ...
Atara Biotherapeutics (NASDAQ: ATRA) has developed Ebvallo (tabelecleucel), a novel second-line immunotherapy for Epstein–Barr virus–positive post-transplant lymphoproliferative disease (EBV-PTLD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback